Back

Teva Launches Innovative Social Media Campaign on Optimal Inhaler Use for World Asthma Day

The ‘Get it Right’ Campaign Calls for Increased Awareness and Dialogue on Correct Asthma Inhaler Technique to Improve Patient Outcomes

Amsterdam, April 24, 2017 – Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) today announced the launch of ‘Get it Right’ – an engaging, disease awareness campaign aiming to challenge the public’s and physician’s mind-set in managing asthma, through education on how to use asthma inhalers correctly. By creating new multimedia content and resources leading up to World Asthma Day, the campaign encourages increased dialogue on the management of this chronic condition.

Poor inhaler technique has been linked to poor asthma outcomes, and the literature suggests shortcomings in correct asthma inhaler use is a key factor in optimal management, with 90% of people living with asthma making at least one inhaler technique error when using their device.1 New data from the CRITIKAL study, which investigated the association between specific inhaler errors and asthma outcomes in 5,000 patients, showed that asthma management should include education on appropriate inhaler use to reduce critical errors.2

A multi-channel, social media initiative, ‘Get it Right’ kicks-off April 24, and runs through to World Asthma Day on 2 May. By providing information & resources for both healthcare professionals and people affected by asthma, the ‘Get it Right’ campaign also aims to foster further dialogue between people affected by asthma and their physicians. The campaign encourages people affected by asthma to spread the message on social media of ‘Get it Right’ when using asthma inhalers with the dedicated hashtag #Getitright and #worldasthmaday

EFA President (European Federation of Allergy and Airways Diseases Patients’ Association), Mikaela Odemyr said: “Following the findings of EFA’s HEY YA report3 about how young asthma patients face their disease and treatment, addressing adherence to asthma treatment, correct technique and tailored support from friends, family and healthcare professionals is crucial for people with asthma.”

“Teva is committed to delivering new, innovative solutions to support the asthma community,” said Janice Canvin, Senior Medical Director, Teva Respiratory. “Ongoing education is of paramount importance in chronic diseases like asthma. This campaign enables patients to participate and have a more effective role in their own treatment, working together with their clinician to achieve optimal inhaler use and disease control.”

Asthma is a chronic (long term) disease usually characterised by airway inflammation and narrowing of the airways, which can vary over time. The World Health Organization (WHO) estimates 235 million people suffer from asthma worldwide.4  In Europe, almost 30 million children and adults under the age of 45 have asthma, with six million of them having severe symptoms. Approximately, one third of Europeans will develop asthma at some time, mostly before the age of 20.5 In the UK alone, there are 5.4 million people with asthma, which means asthma affects one in every 11 people in the UK and one in five UK households.6 

  1. Price DE., et al. Assessment of potential important device errors performed by asthma patients in the global iHARPreview service. Abstract presented at: 7th World Conference of the International Primary Care Respiratory Group; Diagnostic Device Session 2. 24 May 2014. Abstract number: OR-100. 
  2. Price DB., et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. 2017. J Allergy Clin Immunol Pract. S2213-2198(17)30007-7. doi: 10.1016/j.jaip.2017.01.004. [Epub ahead of print]
  3. De Vocht, Joke, et al. Hey Ya! Health Literacy, Young Patients with Asthma and Adherence to treatment: EFA Report and European Recommendations. European Federation of Allergy and Airways Diseases Patients’ Associations, 2015
  4. Chronic respiratory diseases: asthma. WHO website. Available at: http://www.who.int/respiratory/asthma/en/. [Last accessed: 6 April 2017.]
  5. The European Federation of Allergy and Airways Diseases (EFA) Patients’ Association, ‘Inform, Prevent, Care, Involve’ Leaflet, 2014, EFA website: Available at http://www.efanet.org/images/2014/06/EFA-Leaflet_2014.pdf [Last accessed: 10 April 2017.
  6. Asthma UK, ‘Asthma Facts & Statistics’, Asthma UK website: Available at https://www.asthma.org.uk/about/media/facts-and-statistics/ [Last accessed: 10 April 2017.]

About Teva Respiratory

Teva Respiratory develops and delivers high-quality treatment options for respiratory conditions, including asthma, COPD, cystic fibrosis and allergic rhinitis. The Teva Respiratory portfolio is centred on optimizing respiratory treatment for patients and healthcare providers through the development of novel delivery systems and therapies that help address unmet needs. The company’s respiratory pipeline and clinical trial program are based on drug molecules delivered in proprietary dry powder formulations and breath-activated device technologies, as well as a targeted biologic treatment for severe asthma. Through research and clinical development, Teva Respiratory continually works to expand, strengthen and build upon its treatment portfolio to positively impact the lives of the millions of patients living with respiratory disease

About Teva

Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions. With its European headquarters in Amsterdam, the Netherlands, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com

PR Contacts:

Fiona Cohen
Jayson Otke

Armsterdam
Armsterdam

+31 620 08 25 45
+31 682 01 54 07